You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,957,047


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,957,047
Title:GLA monotherapy for use in cancer treatment
Abstract: The present disclosure relates generally to compositions and methods for treating cancer with a glucopyranosyl lipid A (GLA) in the absence of antigen.
Inventor(s): Paya Cuenca; Carlos V. (San Francisco, CA), Ter Meulen; Jan Henrik (Mercer Island, WA)
Assignee: Immune Design Corp. (Seattle, WA)
Application Number:14/256,521
Patent Claims:1. A method of treating a mammal who suffers from cancer, comprising administering an effective amount of a composition comprising GLA, said composition comprising: (a) GLA of the formula: ##STR00009## wherein: R.sup.1, R.sup.3, R.sup.5 and R.sup.6 are C.sub.11-C.sub.20 alkyl; and R.sup.2 and R.sup.4 are C.sub.12-C.sub.20 alkyl; and (b) a pharmaceutically acceptable carrier or excipient; wherein the composition does not comprise antigen.

2. The method of claim 1 wherein R.sup.1, R.sup.3, R.sup.5 and R.sup.6 are undecyl and R.sup.2 and R.sup.4 are tridecyl.

3. The method of claim 1 wherein the mammal is human.

4. The method of claim 1, wherein the composition is an aqueous formulation.

5. The method of claim 1, wherein the composition is in the form of an oil-in-water emulsion, a water-in-oil emulsion, liposome, micellar formulation, or a microparticle.

6. The method of claim 1, wherein the cancer comprises a solid tumor.

7. The method of claim 6, wherein the solid tumor is a carcinoma, a sarcoma or a lymphoma.

8. The method of claim 6, wherein the solid tumor is a primary solid tumor.

9. The method of claim 6, wherein the solid tumor is a secondary solid tumor.

10. The method of claim 1, wherein the cancer is selected from the group consisting of, melanoma, Merkel cell carcinoma, lung cancer, cervical cancer, ovarian cancer, uterine cancer, breast cancer, liver cancer, gastric cancer, prostate cancer, colon cancer, kidney cancer, bladder cancer, brain cancer, and pancreatic cancer.

11. The method of claim 1, wherein the composition is administered by subcutaneous, intradermal, intramuscular, intratumoral, or intravenous injection.

12. The method of claim 1, wherein the composition is administered intranasally or intrapulmonary.

13. The method of claim 1, wherein the composition is administered in conjunction with one or more additional therapeutic agents or treatments.

14. The method of claim 13, wherein the therapeutic agents is an immune checkpoint inhibitor.

15. The method of claim 13, wherein the therapeutic agent is an antibody that activates a co-stimulatory pathway.

16. The method of claim 15, wherein the antibody is an anti-CD40 antibody.

17. The method of claim 13, wherein the therapeutic agent is a cancer therapeutic agent.

18. The method of claim 13, wherein the one or more additional therapeutic agents or treatments is selected from the group consisting of taxotere, carboplatin, trastuzumab, epirubicin, cyclophosphamide, cisplatin, docetaxel, doxorubicin, etoposide, 5-FU, gemcitabine, methotrexate, and paclitaxel, mitoxantrone, epothilone B, epidermal-growth factor receptor (EGFR)-targeting monoclonal antibody 7A7.27, vorinostat, romidepsin, docosahexaenoic acid, bortezomib, shikonin, daunorubicin, oxaliplatin and an oncolytic virus.

19. The method of claim 13 wherein the one or more additional therapeutic agents or treatments is radiation therapy.

20. The method of claim 13 wherein the one or more additional therapeutic treatments is an autophagy inbitor.

21. The method of claim 20 wherein the autophagy inhibitor is chloroquine.

22. The method of claim 2 wherein the mammal is human.

23. The method of claim 2, wherein the composition is an aqueous formulation.

24. The method of claim 2, wherein the composition is in the form of an oil-in-water emulsion, a water-in-oil emulsion, liposome, micellar formulation, or a microparticle.

25. The method of claim 2, wherein the cancer comprises a solid tumor.

26. The method of claim 25, wherein the solid tumor is a carcinoma, a sarcoma or a lymphoma.

27. The method of claim 25, wherein the solid tumor is a primary solid tumor.

28. The method of claim 25, wherein the solid tumor is a secondary solid tumor.

29. The method of claim 2, wherein the cancer is selected from the group consisting of, melanoma, Merkel cell carcinoma, lung cancer, cervical cancer, ovarian cancer, uterine cancer, breast cancer, liver cancer, gastric cancer, prostate cancer, colon cancer, kidney cancer, bladder cancer, brain cancer, and pancreatic cancer.

30. The method of claim 2, wherein the composition is administered by subcutaneous, intradermal, intramuscular, intratumoral, or intravenous injection.

31. The method of claim 2, wherein the composition is administered intranasally or intrapulmonary.

32. The method of claim 2, wherein the composition is administered in conjunction with one or more additional therapeutic agents or treatments.

33. The method of claim 32, wherein the therapeutic agents is an immune checkpoint inhibitor.

34. The method of claim 32, wherein the therapeutic agent is an antibody that activates a co-stimulatory pathway.

35. The method of claim 34, wherein the antibody is an anti-CD40 antibody.

36. The method of claim 32, wherein the therapeutic agent is a cancer therapeutic agent.

37. The method of claim 36, wherein the cancer therapeutic agent is selected from the group consisting of taxotere, carboplatin, trastuzumab, epirubicin, cyclophosphamide, cisplatin, docetaxel, doxorubicin, etoposide, 5-FU, gemcitabine, methotrexate, and paclitaxel, mitoxantrone, epothilone B, epidermal-growth factor receptor (EGFR)-targeting monoclonal antibody 7A7.27, vorinostat, romidepsin, docosahexaenoic acid, bortezomib, shikonin and an oncolytic virus.

38. The method of claim 32 wherein the one or more additional therapeutic treatments is radiation therapy.

39. The method of claim 32 wherein the one or more additional therapeutic treatments is an autophagy inbitor.

40. The method of claim 39 wherein the autophagy inhibitor is chloroquine.

Details for Patent 8,957,047

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 09/25/1998 ⤷  Try a Trial 2039-02-26
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 02/10/2017 ⤷  Try a Trial 2039-02-26
Genentech, Inc. HERCEPTIN HYLECTA trastuzumab and hyaluronidase-oysk Injection 761106 02/28/2019 ⤷  Try a Trial 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.